24756-03-4

Basic information

• Product Name: 3-[(2-methylphenyl)hydrazono]pentane-2,4-dione
• Synonyms: 3-[(2-methylphenyl)hydrazono]pentane-2,4-dione
• CAS NO: 24756-03-4
• Molecular Weight: 218.255
• Mol File: 24756-03-4.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 3-[(2-methylphenyl)hydrazono]pentane-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(2-methylphenyl)hydrazono]pentane-2,4-dione(24756-03-4)
• EPA Substance Registry System: 3-[(2-methylphenyl)hydrazono]pentane-2,4-dione(24756-03-4)

Safety Data

• Hazardous Substances Data: 24756-03-4(Hazardous Substances Data)

Upstream product

• 123-54-6 acetylacetone 
• 95-53-4 o-toluidine 
• 2028-34-4 o-toluene-diazonium chloride 

Downstream Products

• 1238694-77-3 1-(2-methylphenyl)-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one 
• 1369321-24-3 5,7-dimethyl-6-o-tolylazo-3H-thiazolo[4,5-b]pyridin-2-one 
• 1309479-26-2 C₁₉H₁₈N₄O₂ 

Relevant articles and documents

Arylamidrazones as novel corticotropin releasing factor receptor antagonists

The arylamidrazones have been found to be potent corticotropin releasing factor (CRF) receptor antagonists structurally distinct from previously reported CRF1 antagonists. Attempts to modify the arylamidrazone core suggested an important role f

Discovery of 1-[2-Fluoro-4-(1 H -pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1 H -pyrazol-5-yl)pyridazin-4(1 H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor

A novel series of pyridazinone-based phosphodiesterase 10A (PDE10A) inhibitors were synthesized. Our optimization efforts using structure-based drug design (SBDD) techniques on the basis of the X-ray crystal structure of PDE10A in complex with hit compound 1 (IC50 = 23 nM; 110-fold selectivity over other PDEs) led to the identification of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (27h). Compound 27h has potent inhibitory activity (IC50 = 0.30 nM), excellent selectivity (>15000-fold selectivity over other PDEs), and favorable pharmacokinetics, including high brain penetration, in mice. Oral administration of compound 27h to mice elevated striatal 3,5-cyclic adenosine monophosphate (cAMP) and 3,5-cyclic guanosine monophosphate (cGMP) levels at 0.3 mg/kg and showed potent suppression of phencyclidine (PCP)-induced hyperlocomotion at a minimum effective dose (MED) of 0.3 mg/kg. Compound 27h (TAK-063) is currently being evaluated in clinical trials for the treatment of schizophrenia.

Pyridazinone compounds

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0): wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.